Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
PURITAN MEDICAL
RANDOX LABORATORIES

Biomarker Identified for Smoker’s Lung Cancer

By Labmedica International staff writers
Posted on 03 Oct 2013
Image: Immunohistochemical analysis of pulmonary adenocarcinoma stained for ASCL1 (Photo courtesy of LifeSpan BioSciences).
Image: Immunohistochemical analysis of pulmonary adenocarcinoma stained for ASCL1 (Photo courtesy of LifeSpan BioSciences).
A specific pair of proteins may be a successful prognostic biomarker for identifying smoking-related lung cancers, especially pulmonary adenocarcinoma.

The protein achaete-scute homolog 1 (ASCL1) is an important regulatory transcription factor in pulmonary neuroendocrine (NE) cell development, but its value as a biomarker of NE differentiation and as a potential prognostic biomarker remains unclear.

Scientists at the Mayo Clinic (Rochester, MN, USA) examined ASCL1 expression in lung cancer samples of varied histologic subtype, clinical outcome, and smoking status and compared with expression of traditional NE markers. ASCL1 messenger ribonucleic acid (mRNA) expression was found almost exclusively in smokers with adenocarcinoma, in contrast to nonsmokers and other lung cancer subtypes.

Analysis of a compendium of 367 microarray-based gene expression profiles in stage I lung adenocarcinomas identified significantly higher expression levels of the rearranged during transfection (RET) oncogene in ASCL1-positive tumors (ASCL1+) compared with ASCL1− tumors. ASCL1 protein expression by immunohistochemical (IHC) analysis correlated best with synaptophysin compared with chromogranin and the cluster of differentiation CD56 and the neural cell adhesion molecule (CD56/NCAM).

High levels of RET expression in ASCL1+, but not in ASCL1- tumors, was associated with significantly shorter overall survival in stage 1 and in all adenocarcinomas. RET protein expression by IHC had an association with overall survival in the context of ASCL1 expression. When scientists blocked the ASCL1 protein in lung cancer-cell lines expressing both genes, the level of RET decreased and tumor growth slowed. This leads them to believe this mechanism will be a promising target for potential drugs and a strong candidate for clinical trials.

George Vasmatzis, PhD, molecular medical scientist and senior author on the study, said “This is exciting because we’ve found what we believe to be a ‘drugable target’ here. It’s a clear biomarker for aggressive adenocarcinomas. These are the fast-growing cancer cells found in smokers’ lungs.” The study was published on September 16, 2013, in the journal Oncogene.

Related Links:
Mayo Clinic



KARL HECHT GMBH & CO KG
CELLAVISION AB
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: Thin, lightweight, and flexible materials integrate cellulose paper and flexible polyester films as new diagnostic tools to detect biological agents in whole blood, serum, and peritoneal fluid (Photo courtesy of Florida Atlantic University).

Next Generation of Rapid Diagnostic Assays Will Combine Disposable Test Materials with Smartphone Applications

The new generation of rapid diagnostic tests will reflect advances in both materials sciences and instant communications via the Internet and social media. Current diagnostic assays commonly require... Read more

Microbiology

view channel
Image: The Mini-FLOTAC device for examining stool samples for helminths (Photo courtesy of Public Health Laboratory Ivo de Carneri).

Device Diagnostics of Fixed Soil-Transmitted Helminth Infection Assessed

Kato-Katz is a widely used method for the diagnosis of soil-transmitted helminth infection, but fecal samples cannot be preserved, and hence, should be processed on the day of collection and examined under... Read more

Industry News

view channel
Image: In a new collaboration, Abbott will be the exclusive distributor of Sekisui\'s new CP3000 coagulation instrument in various regions, enabling Abbott to provide coagulation testing solutions with the CP3000, a high-throughput system with a compact footprint (Image courtesy of Abbott).

Partnership to Offer New Coagulation Testing Solutions Worldwide

Abbott (Abbott Park, IL, USA) and Sekisui Diagnostics LLC (Lexington, MA, USA), a sister company of Sekisui Medical (SMD; Tokyo, Japan ), have entered an agreement to offer new coagulation testing solutions... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.